Financhill
Back

Brainstorm Cell Therapeutics Quote, Financials, Valuation and Earnings

AI DIVIDENDS: No. 1 Way to Collect Passive Income

Click here to get it for free.
Sell
7

BCLI
Brainstorm Cell Therapeutics

Last Price:
1.91
Seasonality Move:
2.27%

7 Day Trial

ALL ACCESS PASS

$ 7

#1 ETF for Monthly Dividend

Click HERE to learn more.

Brainstorm Cell Therapeutics Price Quote

$1.91
+0.04 (+2.14%)
(Updated: November 1, 2024 at 10:35 AM ET)

Brainstorm Cell Therapeutics Key Stats

Sell
7
Brainstorm Cell Therapeutics (BCLI) is a Sell

Day range:
$1.81 - $1.95
52-week range:
$1.81 - $11.89
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0%

Volume:
34.1K
Avg. volume:
75.2K
1-year change:
-18.52%
Market cap:
$9.9M
Revenue:
$0
EPS:
$-3.45

How Much Does Brainstorm Cell Therapeutics Make?

Data Unavailable

Is Brainstorm Cell Therapeutics Growing As A Company?

Data Unavailable

Brainstorm Cell Therapeutics Stock Price Performance

What Is Brainstorm Cell Therapeutics 52-Week High & Low?

Brainstorm Cell Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Brainstorm Cell Therapeutics?

Is Brainstorm Cell Therapeutics Cash Flow Positive?

Brainstorm Cell Therapeutics Return On Invested Capital

Data Unavailable

Brainstorm Cell Therapeutics Earnings Date & Stock Price

Brainstorm Cell Therapeutics Competitors

Brainstorm Cell Therapeutics Dividend Yield

Brainstorm Cell Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -33.33%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 22.84
Upside from Last Price: 1121.21%

Major Shareholders

  • How many BCLI shares are owned by institutional investors?
    14M BCLI shares are owned by institutional investors
  • How many BCLI shares are owned by insiders?
    4.1M BCLI shares are owned by insiders